Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals Inc.
WKN: 881535 / Symbol: REGN / Name: Regeneron / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
869,20 €
-0,59 %
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at TD Cowen from $900.00 to $1,000.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,045.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $1,076.00 price target on the stock, up previously from $884.00.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Barclays PLC from $935.00 to $1,020.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1,076.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at BMO Capital Markets from $1,055.00 to $1,082.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Royal Bank of Canada from $1,076.00 to $1,110.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Royal Bank of Canada from $1,096.00 to $1,184.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating and a $1,125.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Morgan Stanley from $1,104.00 to $1,115.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,135.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,135.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1,189.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Bank of America Co. from $710.00 to $720.00. They now have an "underperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at TD Cowen from $1,020.00 to $1,030.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Ford Motor Co. diskutieren